SUPERNOVA: A Phase I/III Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of AZD7518 for Pre-exposure Prophylaxis in Participants with Conditions Causing Immune Impairment
AZD7518, a combination of 2 novel mAbs AZD3959 and AZD3152, is being developed to
have broad neutralizing activity across known SARS-CoV-2 variants of concern for a
pre-exposure prophylaxis of COVID-19 indication.
Study details
Study-ID: 2022-002378-95
Study-ID: 2022-002378-95
DZL Disease Area: ROR, DPLD
DZL Disease Area: ROR, DPLD
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: CPC-M
DZL Participating Sites: CPC-M
Start Date: 08.01.2023
Completion Date: 14.01.2024
Status: Closed
Status: Closed
DZL recruiting center
Disease: Patients with conditions causing immune impairment
Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu.
Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.
